Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Otolaryngol Head Neck Surg. 2022 Mar 1;167(5):860–868. doi: 10.1177/01945998221083506

Figure 3. Viability by Tumor, Radiation, and RI-1 Dose.

Figure 3.

Although RI-1 (5 and 10 μM) enhanced radiation toxicity in most tumors, RI-1 was less effective at reducing viability with VSA60 and VSA69.

HHS Vulnerability Disclosure